Skip to content

Earnings call

Jagsonpal Pharmaceuticals Q3 FY25 earnings call

By . Assembled by software from the company's transcript. Not reviewed by a person.

Transcript filed .

The company expects its products to grow 3% to 4% in volume and 3% to 5% from price, with the rest of growth coming from new product launches. The company reported 57% top-line growth, including 27% organic growth, in Q3FY25; the remainder came from inorganic acquisition. Jagsonpal's gynae business accounts for 50% of its revenues, and three out of its four divisions are gynae focused.

The numbers management gave

Results

  • The company reported 57% top-line growth, including 27% organic growth, in Q3FY25; the remainder came from inorganic acquisition.
    Show source
    While we have reported a growth of, I think, 57% on top line, the organic growth is 27%, while the rest is coming because of inorganic acquisition.
  • The company reported 27% total growth and 8% organic growth on a YTD basis; the balance of total growth came from inorganic initiatives.
    Show source
    It has moved to 8% as against the total growth of 27% that has been reported during the period, with the balance coming of inorganic initiatives.
  • The company typically generates between INR 15 crores to INR 18 crores of operating cash every quarter.
    Show source
    Because typically we generate between INR 15 crores to INR 18 crores of operating cash every quarter.
  • Yash Pharma, now a division of Jagsonpal Pharmaceuticals Limited rather than a separate company, has revenue broadly in the region of INR 14 crores per quarter.
    Show source
    But it is broadly in the region of INR 14 crores per quarter.
  • Current-quarter ESOP cost was INR13 million collectively, slightly lower because of the reversal of ESOP granted to the CFO after his resignation.
    Show source
    It's INR13 million, I think, collectively.
  • Internal sales are about a third of where they were about 18 months back; the decline has been arrested and the company saw the first green shoots from December, with a marginal turnaround and stabilization expected to begin reflecting in growth from Q4 onwards.
    Show source
    Today, probably our internal sales are about a third of where we were about 18 months back.
Show 1 more statement

Money and capital

  • The company will utilize its cash for inorganic strategies, with any acquisition required to fit its strategy and pricing criteria.
    Show source
    I think I have been very categorical in my previous calls that this will be utilized for inorganic strategies.

What it expects ahead

What management expects

  • The company expects its products to grow 3% to 4% in volume and 3% to 5% from price, with the rest of growth coming from new product launches.
    Show source
    We obviously would like our products to grow between 3% to 4% in terms of volumes, another 3% to 5% comes out of price and the rest comes out of new product launches.
  • Recent launches FeProtein and LycoRed M have monthly sales crossing INR20 lakhs per month and are expected to be volume and growth drivers for the coming year.
    Show source
    Some of our recent launches and I would like to highlight two of them, FeProtein and LycoRed M are now beginning to catch up in the marketplace, and monthly sales have started crossing INR20 lakhs per month .
  • The company expects its cash balance to be fairly close to the INR 150 crores mark by the end of the year, give or take INR 1 crores or INR 2 crores.
    Show source
    Manish Gupta: So cash balance, I think we are well on track to get fairly close to the INR 150 crores mark, give or take INR 1 crores or INR 2 crores here and there.
  • ESOP cost run rate for the next 2 quarters would be INR 17 million to INR 18 million per quarter and, starting September’25, would go down to about INR 10 million per quarter because most of the ESOPs were granted in September’22 and the next reset technically happens in September ’25.
    Show source
    Our current run rate ESOP cost, for next 2 quarters, would be in the region of INR 17 million to INR 18 million per quarter.
  • Yash Pharma business accounts for roughly 20% of Jagsonpal Pharmaceuticals Limited's revenues, and is expected to remain between 18% to 22% of overall organization revenues unless there is another acquisition or inorganic strategy.
    Show source
    Unless there is another acquisition or inorganic strategy, this number should stay in the region of between 18% to 22% of our overall organization.
  • The company is targeting 12% to 14% top-line growth on a stable basis and an overall blended EBITDA margin between 22% and 23% this year; the first 9 months are in line with that, and the company expects 120 to 150 bps margin expansion year on year going forward.
    Show source
    Going forward, we are looking at anywhere between 120 to 150 bps margin expansion year on year.

What it is building and selling

Segments

  • Jagsonpal's gynae business accounts for 50% of its revenues, and three out of its four divisions are gynae focused.
    Show source
    Manish Gupta: Our gynae business still accounts for 50% of our revenues.
  • Jagsonpal's broad portfolio mix is not expected to change without inorganic initiatives, although 1%-2% may change on its own.
    Show source
    But of course, 1%-2% here and there may change on its own, but otherwise, the broad mix is not expected to change without inorganic initiatives.
  • MemUp numbers lag way behind what it had anticipated, although the product provides talking points in doctors' chambers and may be bringing other business.
    Show source
    Manish Gupta: Yes, so from a business angle, MemUp numbers lag way behind what we had anticipated.
  • Jagsonpal is the eighth largest prescribed company in the gynae chambers.
    Show source
    Actually, we are the eighth largest prescribed company in the gynae chambers, so that's really our core strength.

Everything else said on the call

What management stressed

  • The company is undertaking doctor training and education through its MySakhi platform, which initially targeted customers or potential women approaching menopause age.
    Show source
    And our entire CSR initiative under MySakhi platform, while initially we had started that for customers or potential women approaching menopause age, but now we are undertaking a lot of doctor conversations on that platform as well.

People and governance

  • The company does not foresee any increase in its MR strength, give or take 3% or 4% here and there, and does not foresee any jump or change in MR strength.
    Show source
    On our own, we do not foresee any increase in our MR strength, give or take 3 % or 4% here and there.
  • The company expects its new CFO to onboard within the next 60 days, during the current financial year which ends in March.
    Show source
    I think we should have him onboarding us within the next 60 days.

Other

  • MR productivity is closer to INR2.5 lakhs per month.
    Show source
    Closer to INR2.5 lakhs per month.

What the company said on its earnings call, taken from its own transcript. Not advice.

Questions and answers

  1. Question

    Aditya Chheda: Okay, and the second question is on the issues that we had discussed in the previous call. One regarding the spurious drugs and the competitive intensity in the Dydrogesterone products. So, has the market share loss been arrested? And if there are any actions that are taken from our end, and if you have any further updates to share regarding the same, that would be helpful. Yes, these are my questions.

    Answer, manish gupta

    Manish Gupta: Thank you for the questions. So, coming to our 9-month and 3-month performance, split into organic growth versus inorganic growth. So, first let me give you the quarter 3 update. While we have reported a growth of, I think, 57% on top line, the organic growth is 27%, while the rest is coming because of inorganic acquisition. On a YTD basis, the growth numbers are 8% organically. So, organic growth is now also inching up. It has moved to 8% as against the total growth of 27% that has been reported during the period, with the balance coming of inorganic initiatives.

  2. Question

    Aditya Chheda: Yes. Page 3 of 12 Jagsonpal Pharmaceuticals Limited January 23, 2025 Manish Gupta: Now, difficult to give a value and a volume split and a price increase because of diverse nature of products.

    Answer, manish gupta

    But all in all, I would say the volume growth would be about a third of the 8% overall growth that we have reported. And I'm talking of a like-to-like business. Coming to Indocap and Divatrone, which were two of our problem matters, especially Indocap had a counterfeit issue. Most of that material was flushed out by the end of last year and the product is back on strong growth rate during the current year. In fact, it has become the first INR 50-crores brand as per IQVIA from Jagsonpal’s stable. Divatrone, the market environment hasn't changed much. It remains hyper-competitive.

    Answer, manish gupta

    Having said that, while we have a fairly big drop compared to our performance last year, the new performance has stabilized. And in fact, we have started getting into a marginal growth territory starting from December. So clearly, I think Indocap has reflected a very strong growth internally given that counterfeit matters are over and translating into a first INR 50-crores brand for us in ICBR, and Divatrone is beginning to change as we speak.

  3. Question

    Neelam Punjabi: Yes, Thanks for the opportunity and Congratulations on some good set of numbers. My first question is on the Yash Pharma acquisition. So post the acquisition, if you could please highlight what are the strategic changes that we have brought about, how is the integration panning out, and how has the margin trajectory improved from the 12% that you had highlighted in the last quarter?

    Answer, manish gupta

    Manish Gupta: So obviously, this is a long journey as far as Yash Pharma business acquisition is concerned. Some of the immediate changes that we had made to the business was the way they used to discount or offer free goods. Those have been rationalized. We obviously are working on reducing the cost of goods, but I think also we have been able to bring down their overall cost of operations, which includes logistics and our distribution costs as well. All in all, the business is tracking well for us. It is on growth on a YTD basis. Compared to what they've done at their own end, we are on a positive high single-digit growth despite all the changes that we have brought in the field.

    Answer, manish gupta

    From a profitability angle, they are now very close to the overall corporate margin that we have been displaying as an organization. A lot of gap has been already bridged and they are now very, very close to our overall corporate margins. Does that answer your question?

  4. Question

    Neelam Punjabi: Yes, absolutely. And we have been guiding for 12% to 14% growth beyond FY25. So if you could please highlight what are the key drivers that will take us to this 12% to 14% growth? Page 4 of 12 Jagsonpal Pharmaceuticals Limited January 23, 2025 Manish Gupta: I think the drivers will be nothing different from what are the drivers for the industry.

    Answer, manish gupta

    We obviously would like our products to grow between 3% to 4% in terms of volumes, another 3% to 5% comes out of price and the rest comes out of new product launches. Some of our recent launches and I would like to highlight two of them, FeProtein and LycoRed M are now beginning to catch up in the marketplace, and monthly sales have started crossing INR20 lakhs per month . And therefore, we believe these can be reasonably good volume and growth drivers for us for the coming year. So all in all, I would say a third, third, and third between price, volumes, and new products. Not very different from the industry. And of course, this comes with a lot of executional challenges and opportunities.

  5. Question

    Neelam Punjabi: Got it. This is helpful. My next question is on the divisionization of Field Force that we had undertook. So how is it playing out?

    Answer, manish gupta

    Manish Gupta: Yes, so this was undertaken in FY24, which was within 6 months or 9 months of our acquisition or change of control in the organization. So it took about 6 to 8 months to stabilize, but now it is all very, very stable, and it has given us headroom for new prod uct introduction. And that was the fundamental reason for divisionization. The aim was to have enhanced focus in doctor’s chamber and, of course, new product introduction. So in both the perspectives, now it is stabilized and giving us that headroom for growth.

  6. Question

    Neelam Punjabi: Got it. And on a gross margin, so we've seen a significant improvement there on a Y-o-Y basis. So where should these gross margins settle? You know, some of the domestic focus companies are at almost 80% gross margin. So can we expect our company to head towards that direction?

    Answer, manish gupta

    Manish Gupta: 80% is going to be challenging. It's not that we don't want to get there. It would be lovely to get there. But having said that, I would expect a 50 to 75 bps gross margin improvement year on year.

  7. Question

    Neelam Punjabi: Got it. Okay. And my last question is on our cash balance. So can we get back to the INR150 crores of cash by the end of the year? And what is the strategy of deploying our cash balance? Inorganically also, what is the strategy, if you could highlight?

    Answer, manish gupta

    Manish Gupta: So cash balance, I think we are well on track to get fairly close to the INR 150 crores mark, give or take INR 1 crores or INR 2 crores here and there. Because typically we generate between INR 15 crores to INR 18 crores of operating cash every quarter. So I foresee us very, very close to the mark that we had guided to. Utilization of cash, also nothing changes. I think I have been very categorical in my previous calls that this will be utilized for inorganic strategies. But any inorganic acquisition has to fit both our strategy and also pricing criteria. Because a mistake there can be very expensive for the organization.

    Answer, manish gupta

    So we are a disciplined buyer. The target has to fit our strategy as also our expectations around valuation. Page 5 of 12 Jagsonpal Pharmaceuticals Limited January 23, 2025 In that case, we'll utilize that cash else we'll either continue to sit on cash. And if shareholders demand, we are happy to return the cash back to the shareholders in dividend or whatever form.

  8. Question

    Neelam Punjabi: Any specific focus areas for acquisition?

    Answer, manish gupta

    Manish Gupta: See, this is a difficult question. I look at acquisitions in two forms. One is filling strategic gaps in our portfolio. Because even within derma, gynae and ortho, there are significant gaps in our portfolio. So there are opportunities around that. And then potentially opportunity to expand therapeutic presence, which is of course another possibility. So both these areas are open for acquisition.

    Answer, manish gupta

    Having said that, fundamentally we will be looking at India-centric businesses for acquisitions and not otherwise.

  9. Question

    Alisha Mahavala: Hi. Thank you for the opportunity. Sir, can you please call out what has been the revenue of Yash Pharma in this quarter and in Q2?

    Answer, manish gupta

    Manish Gupta: I don't have a precise number. Because Yash Pharma is no longer a separate company. It's one of the divisions and there has been certain cross-leveraging of portfolio between each other. But it is broadly in the region of INR 14 crores per quarter.

  10. Question

    Alisha Mahavala: And if we could just quickly touch upon what is the MR productivity currently and are we still looking at expanding our MR strength? We are at about 900 MR. So where do we expect this number to go?

    Answer, manish gupta

    Manish Gupta: MR productivity is a mathematical exercise but we are sub INR3 lakhs per month. Closer to INR2.5 lakhs per month. So clearly there is a significant scope of improving MR productivity. I don't think we'll ever be very high MR productivity given the nature of our products which are very doctor-intensive products. So it requires a lot of hard work by the MR. But having said that, there is enormous scope of improvement. On our own, we do not foresee any increase in our MR strength, give or take 3 % or 4% here and there. But otherwise, we have complete coverage that is required as an organization and I don't foresee any jump or change in our MR strength.

    Answer, manish gupta

    Productivity is something which we are working on.

Show 12 more questions
  1. Question

    Alisha Mahavala: And lastly, if you could just call out in 9 months of YTD, what has been the contribution from new product launches?

    Answer, manish gupta

    Manish Gupta: I don't have this data handy. But also of course it is compromised because Ashish is no longer there. So can I get back to you with this data? Page 6 of 12 Jagsonpal Pharmaceuticals Limited January 23, 2025 Alisha Mahavala: Sure.

  2. Question

    Aditya Chheda: A bookkeeping one on ESOP accounting. Beyond FY25, what are the charges that we are looking to hit in the P&L in ‘26 or ‘27? And the other question was, is it possible to quantify the gross margin differential between the portfolio that we have acquired and the base business that we would have? These are the two questions.

    Answer, manish gupta

    Manish Gupta: So I'll take the second one first because that's easier. Clearly the gross margins of Jagsonpal business are slightly ahead of the acquired Yash Pharma business and that is purely coming out of the nature of the portfolio. Because JPL portfolio is largely hormonal products, hormones are given in micrograms and milligrams and therefore the API cost is negligible even though it is very expensive. As compared to Yash Pharma products, Yash Pharma products are more mass consumption products. So therefore the gross margins are slightly lower, though not very, very different. That's question one. Now coming to the ESOP cost that you saw.

    Answer, manish gupta

    The current quarter ESOP costs are slightly lower. It's INR13 million, I think, collectively. This is also on account of the reversal of ESOP for the CFO, which we have granted and therefore had to be reversed post his resignation. Our current run rate ESOP cost, for next 2 quarters, would be in the region of INR 17 million to INR 18 million per quarter. And starting September’25, it will go down to about INR 10 million per quarter. And this is basically because of the way accounting works. Since most of these ESOPs were granted in September’22, therefore the next reset technically happens in September ’25.

  3. Question

    Aditya Chheda: Got it, sir. And when you mentioned that it is slightly lower, is it possible to quantify that number in terms of gross margin? Maybe 400, 500 bps or thereabouts.

    Answer, manish gupta

    Manish Gupta: So I mentioned that INR 4 million is the difference. For next 2 quarters, the run rate ESOP cost will be INR 17 million.

  4. Question

    Aditya Chheda: My question was on the gross margin differential of the acquisition portfolio. The differential, you spoke that it will be lower, but is it possible to quantify?

    Answer, manish gupta

    Manish Gupta: This is something we would like to avoid.

  5. Question

    Ankur Bhadekar: Hi, sir. First of all, congratulations for a good set of numbers. My question was on the Yash Pharma business. How much contribution in percentage terms are you expecting from that business for FY25 and beyond in the coming years? Page 7 of 12 Jagsonpal Pharmaceuticals Limited January 23, 2025 Manish Gupta: Yash Pharma business accounts for roughly about 20% of our revenues.

    Answer, manish gupta

    And I don't think that number will change much, because our core business will also grow and Yash Pharma business will also grow. Unless there is another acquisition or inorganic strategy, this number should stay in the region of between 18% to 22% of our overall organization.

  6. Question

    Ankur Bhadekar: And how do you see the business going forward in terms of your gross margins or EBITDA margins considering the acquisition of Yash Pharma? Blended margins?

    Answer, manish gupta

    Manish Gupta: The guidance that we had given in the first call continues to stay intact. So we are targeting, this year is of course a big change because of reported numbers capturing Yash Pharma and what we call Unify division for us going forward. But going forward, on a stable basis, we are looking at 12% to 14% top line growth. And a margin expansion this year, we have been guiding towards an overall blended EBITDA margin at between 22% and 23%. I think the first 9 months are in line with that. And we expect to continue that going forward. Going forward, we are looking at anywhere between 120 to 150 bps margin expansion year on year.

  7. Question

    Abhishek Singhal: Sir, thanks for taking my question. Can you just throw some light on your thought process around building the trade generic business in India, if at all? And will that require some amount of corporate bonding around Jagsonpal to build it? So your thought process on how trade generic plays out for you will be very helpful.

    Answer, manish gupta

    Manish Gupta: I think trade generic is an important part of business in India. And every big company is in it, without exception. On a smaller base, of course, this is an area growing faster. Jagsonpal also has a small trade generic division even prior to us getting into it. So it has a good and growing trade generics business for us as well. But you have to understand that trade generic programs and customers are different from the normal branded part of business, which is a doctor intensive part. And Jagsonpal strength is, which is why if you kind of relate and we can have an offline discussion as well.

    Answer, manish gupta

    I have always highlighted that Jagsonpal’s core product portfolio is a highly doctor intensive portfolio. Less prone to trade generics, simply because the hormonal products will not be taken without a doctor's prescription. So our portfolio of trade generics is very different from our core branded portfolio. Trade generics is all about cough and cold and all the general usage products largely. And some chronic segments because that's where costs are important. So in chronic segment if you are on diabetes and all, which you are taking lifetime, then people tend to go for cheaper alternatives. But our range of products are highly pregnancy related, pregnancy protection and all that.

    Answer, manish gupta

    Therefore, highly doctor intensive and therefore less prone to trade generics. But as a segment Page 8 of 12 Jagsonpal Pharmaceuticals Limited January 23, 2025 trade generics I believe will stay and will continue to grow. And this is the way to classically look at Indian population. We are multi price point markets. So both will continue to do well.

  8. Question

    Abhishek Singhal: Thank you. And so you spoke about 150 basis points kind of a margin expansion year on year to anticipate. And to a previous question you had talked about 75 bps coming from gross margin. So given where our productivity is on the sales force side, doesn't this look like --because my sense was that even the sales force productivity should be a significant leverage driver. And to top that if we have some gross margin expansion, couldn't the EBITDA margin expansion be much higher than what you are guiding to? And also if you compare with other pure play domestic focused companies like ours, their margin profile is going to almost 35% odd number. Is it to do with that they have

    Answer, manish gupta

    Manish Gupta: So Abhishek, you always pick up the higher part of the guidance and never the mid part of the guidance. So I must give that to you. So I expect 120 bps to 150 bps that you only picked 150 bps. Having said that, on a serious note, it's not that I don't want to grow my margins and take it to 35%. I would love to do that. But this is a journey. And you cannot reach the destination without going through this journey.

    Answer, manish gupta

    So therefore, yes, if we are lucky and if we end up with the top end of our growth target, maybe our margin expansion will be 200 bps in the next couple of quarters or around that. But I know the reality because certain things work out and certain things do not work out when you are running strategy across 300 people in each division. Therefore, what we guide towards is something where we think given all the pluses and minuses that happen in business, you'll end up with. But you are right, we still have a long way to cover between where we are versus where the top companies in this industry are. We will bridge this part of the journey as we go along. A lot of it will come from MR productivity. I do not believe manufacturing has any role to play for our lower margins.

  9. Question

    Abhishek Singhal: Got it, sir. This is very helpful. Thank you. And so one last question around new product launches, because that's an extremely important element given the fact that you said that you had a very strong network with the doctors. So how are you working on that? How many products should we expect launched every year? And to some extent, because now it's been two years since you've come on board, like how is this journey of new product launches playing out? Are you happy with the way things are going out there? Some sense around that would be helpful, sir.

    Answer, manish gupta

    Manish Gupta: So this is an area I work very extensively in my personal capacity. Strategically, we have moved away from products which will become mass products in terms of volumes and will end up seeing enormous amount of competition. So, if you see strategically, all our new products are conceptual products. Page 9 of 12 Jagsonpal Pharmaceuticals Limited January 23, 2025 Be it FeProtein, be it LycoRed M, MemUp, Queezy-ER. They are all small subsets of market. They require hard work at the doctor's chamber, but these are, once you get it, fundamentally these businesses stay, so that's the strategy around new product launches. We will not get into like Elagolix is going off patent and there will be a lot of companies launching that.

    Answer, manish gupta

    We will stay away in those kinds of launches. All our products will be slightly differentiated and hardworking or products requiring hard work in doctor's chamber. We have a good portfolio already in terms of pipeline. And the way to see it is we should be launching between 8 to 10 new products each year, about two products in every division. And we currently have four divisions.

  10. Question

    Abhishek Singhal: Thank you, sir. All the best.

    Answer, manish gupta

    Manish Gupta: Yes. So we are fairly advanced in our CFO search. It's going well. I think we should have him onboarding us within the next 60 days. And that's why in my opening remarks, I did mention within the current financial year, which ends in March. See, basically what we skills we see for CFO, we are not a complex business, and nor are we a debt-ridden business. So fundamentally, the character we require in our CFO is disciplined approach.

    Answer, manish gupta

    It is all about collections, maintaining tight controls on collections, and maintaining a hawk -eye on how we operate, because it's a kind of retail business with thousand MRs. So somebody has to have that hawk-eye and a feel of business and feel of numbers. Because what we are dealing at the MR level is a few thousand in terms of every invoice. So that's, I mean, detail-oriented, highly compliance-oriented, and highly discipline-oriented in terms of collections. And keeping a hawk-eye on cash balances is what we are seeking as a CFO in the organization. There are no complex accounting requirement s at our end, to be candid. Pratik: Okay. What I was trying to get to was, are you looking for someone with experience in M&A or some sort of different skills?

    Answer, manish gupta

    But maybe you could talk about it a little bit.

    Answer, manish gupta

    Manish Gupta: So M&A will be desirable, but to be candid, my own personal core strength is M&A. And I would have done more transactions than most bankers in this country with over 20 years of M&A experience. So that's not a skill we really require from a CFO angle. Pratik: Sounds good. And could you just give me some color on your launch on MemUp? How is it being received in the market, and what are you guys doing to drive the revenue up there?

    Answer, manish gupta

    Manish Gupta: Yes, so from a business angle, MemUp numbers lag way behind what we had anticipated. But from a noise angle, it gives us good talking points in the doctor's chamber. But I don't think it Page 10 of 12 Jagsonpal Pharmaceuticals Limited January 23, 2025 translates into MemUp business, but probably we may be getting other business on account of MemUp. We are doing a lot of work, scientific work around it, organizing doctor's interaction. So what we found actually in this process is that doctors require far more work than even the customers or consumers of this product. And therefore, a lot of emphasis is being done or we are undertaking for doctor training or doctor education in this regard. And our entire CSR initiative under MySakhi platform, while initially we had started that for customers or potential women approaching menopause age, but now we are undertaking a lot of doctor conversations on that platform as well.

    Answer, manish gupta

    So a lot of hard work, not at all reflecting in the numbers that we had expected for the product, but giving us good engagement with the doctors is what I would say. Pratik: Awesome. Thank you, Manish, thank you for clearing it up. And your hard work is clearly showing, so congrats.

    Answer, manish gupta

    Manish Gupta: Yes. So partly I had addressed this in the initial part, but I will be happy to repeat again, Amresh. Basically, overall I think the molecule has stabilized. It has stopped growing as it had been growing in the past. Clearly, we are seeing that gradually as the product that came up in the market starts expiring, some of the smaller players will start going away. At our own end, the decline has been arrested. It is, of course, a fraction of what it used to be 18 months back.

    Answer, manish gupta

    Today, probably our internal sales are about a third of where we were about 18 months back. But the decline has been arrested and we are seeing the first green shoots from December. So there has been a turnaround in a way, though marginal, from December on wards. Does that answer? And on a quarter basis, I think overall we are now beginning to both stabilize for sure and should start reflecting in growth from Q4 onwards.

  11. Question

    Amresh Kumar: Okay. And my second question would be on your optical mix of ortho versus gynae versus Pedia that you see in your mix. And where are you right now and where you would like to go about?

    Answer, manish gupta

    Manish Gupta: Our gynae business still accounts for 50% of our revenues. So we are predominantly a gynae company as an organization. Whereas in fact, three out of our four divisions are gynae focused Page 11 of 12 Jagsonpal Pharmaceuticals Limited January 23, 2025 divisions. And this is our core strength. Within gynae, we are in the top ten. Actually, we are the eighth largest prescribed company in the gynae chambers, so that's really our core strength. Between the rest of the other three segments, ortho would account for about 20% of revenues.

    Answer, manish gupta

    And between Pedia and Derma would be about 12%-15% each. So that's a broad portfolio mix. Will it change on its own? Answer is no, because there are no rockets in any of the product areas or any of the categories. So all businesses grow and therefore on its own the mix will not change, excepting for inorganic strategy. That will only cause a change in our portfolio mix. But of course, 1%-2% here and there may change on its own, but otherwise, the broad mix is not expected to change without inorganic initiatives.

  12. Question

    Amresh Kumar: Thank you so much for the opportunity. And best of luck.

    Answer, manish gupta

    Manish Gupta: Yes, thank you. Thank you all participants for your valuable questions and engagement today. We appreciate your interest in Jagsonpal Pharmaceuticals. Should you have any further inquiries and or additional information requirement, please do not hesitate to contact our Investor Relations team at Go India Advisors. We remain committed to engaging with all of you, fostering transparent communication, as we continue advancing our objectives of creating value for our stakeholders. Thank you once again for your participation and wish you a great day ahead. Thank you all.

Questions about this call

When was the Jagsonpal Pharmaceuticals Q3 FY25 earnings call transcript filed?
Jagsonpal Pharmaceuticals filed the transcript with the exchange on 29 Jan 2025. This page is built from that transcript.
What does this page list?
21 statements from the transcript across 7 topics, 14 of them with a figure. Each statement is shown with the transcript sentence it came from.
Are the analysts' questions included?
Yes. 22 questions and management's answers are listed in the order they were asked, as the transcript prints them.
Who wrote this page?
DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.
Research and analysis only, not investment advice. Every statement on this page is the company's own, taken from its transcript; DalalOS adds no view on it and is not a SEBI-registered investment adviser. Something wrong? Report an error.